

Official Journal of the Neuroscience Society of Nigeria (NSN) ORIGINAL ARTICLE

https://doi.org/10.47081/njn2016.7.2/002 ISSN 1116-4182

# Histological and Immunohistochemical Assessment of the Cerebral Cortex Following Potassium Bromate Intoxication in Wistar Rats

Agnes A. Nwakanma<sup>1</sup>, Moses B. Ekong<sup>2</sup>, Chukwuebuka O. Elemuo<sup>1</sup>, Mokutima A. Eluwa<sup>3</sup>, Igwe J. Okafor<sup>1</sup>, Ann C. Idaguko<sup>4</sup>

<sup>1</sup>Department of Anatomy, Faculty of Basic Medical Sciences, Chukwuemeka Odumegwu Ojukwu University, Uli, Nigeria <sup>2</sup>Department of Anatomy, Faculty of Basic Medical Sciences, University of Uyo, Uyo Nigeria <sup>3</sup>Department of Anatomy, Faculty of Basic Medical Sciences, University of Calabar, Calabar, Nigeria <sup>4</sup>Department of Anatomy, Faculty of Basic Medical Sciences, Madonna University, Elele, Nigeria

Received: ..... August 2015 Accepted: ..... November 2015

## ABSTRACT

Potassium bromate (KBrO<sub>3</sub>) is classified as mutagenic and carcinogenic although used in food and cosmetics industries, and also found in drinking water as a by-product of disinfection. Industrial pollution of drinking water and its ability to cross the blood-brain barrier lead to the investigation of its effect on the cerebral cortex. Twenty adult Wistar rats with average weight of 200 g were divided into four groups designated as 'A' for the control group, and 'B, C and D' for the test groups, with each group having five rats. All animals had free access to feed and water. The control group did not receive any treatment, while the test groups received 0.1 mg/kg, 0.2 mg/kg, and 0.3 mg/kg of KBrO<sub>3</sub> respectively, for 28 (twenty-eight) days through orogastric tube. On the 29th day, all animals were anaesthetized using ketamine hydrochloride (100 mg/kg, i.p.), and the brains were perfused transcardially with 0.9 % buffered saline followed by 10 % buffered formalin. The brains were removed and further preserved in 10% buffered formalin. The cerebral cortex was dissected, processed for paraffin sectioning and stained for histological study using Haematoxylin and Eosin technique and astrocytes immunolabelling with glial fibrillary acidic protein (GFAP). Results revealed that KBrO<sub>3</sub> caused histological alterations and degeneration of neurons and astrocytes in the KBrO<sub>3</sub> test groups especially the high dosage groups. These effects were dose dependent, and hence the degeneration of cells may lead to the functional impairment of the cerebral cortex.

Keywords: Cerebral cortex, histology, potassium bromate, Glial fibrillary acidic protein, Wistar rat

## INTRODUCTION

Potassium bromate (KBrO<sub>3</sub>) is a nephrotoxic and carcinogenic substance although used in food and cosmetics industry, and also found in drinking water as a by-product of disinfection (Kurokawa et al. 1990). KBrO<sub>3</sub> is a colourless, odourless and tasteless white crystal/powder initially used as a food additive and was a commonly used flour enhancing agent in Nigeria (Emeje et al. 2010). Its use in baking was to ensure an increase loaf volume and texture of the bread rise in the oven (Nakamura et al. 2006) probably due to its oxidizing properties.

The maximum concentration of  $KBrO_3$  allowed in bread by the United States Food and Drug Agency (FDA) was 0.02 mg/kg (WHO 1992). However,  $KBrO_3$ degrades essential vitamins in bread (Ekop et al. 2008), and has been classified by the International Agency for Research on Cancer (IARC) as a possible human carcinogen based on sufficient evidence that KBrO<sub>3</sub> is carcinogenic and mutagenic in experimental

Correspondence: Agnes A. Nwakanma, M.Sc., Department of Anatomy, Faculty of Basic Medical Sciences, Chukwuemeka Odumegwu Ojukwu University, P.M.B 02, Uli, Nigeria. Email: akudoekeoma@yahoo.com; +2348037738053 animals (IARC 1986). KBrO<sub>3</sub> has also been classified as a genotoxic carcinogen based on positive results in the Ames (Ishidate et al. 1984), chromosome aberration (Ishidate et al. 1984) and micronucleus tests (Hayashi et al. 1988). It is reported to be carcinogenic in the kidney, thyroid, and mesothelium in rats, while being carcinogen in the kidney in mice (DeAngelo et al. 1998; Wolf et al. 1998). Furthermore, Umemura et al. (2006) also reported *in vivo* mutagenic effects of KBrO<sub>3</sub> in the kidneys of rats.

The lethal dose (LD50) of KBrO<sub>3</sub> in the Wistar rat is higher in the female than in the male, and is reported to be 160-180 mg/kg body weight (Kawachi et al. 1980). Oinuma et al. (1974) reported increase in the levels of cholesterol and phospholipids in the brain and kidney of mice after a single intragastric administration of KBrO<sub>3</sub>. It is reported to alter cholesterol and vitamin E levels (Keser et al. 2011), cause oxidative damage and histological changes in the kidney (Le Page et al. 1995; Wahba and Ibrahim 2013) and degenerative changes in the liver and the brain (Akanji et al. 2008; Oyewo et al. 2013; Wahba and Ibrahim 2013). Though there are some reports on the effect of KBrO<sub>3</sub> on the brain, this is however limited probably due to the ban on its use.

This study arose due to the differing concentrations of  $KBrO_3$  in contaminated drinking water humans are exposed to. As the water concentrations of  $KBrO_3$  cannot be standardized because of differences in the environment, this has really motivated the need for this study on the effect of a high bioavailability of  $KBrO_3$  in the brain with emphasis on the cerebral cortex.

## MATERIALS AND METHODS

20 female Wistar rats with average body weight 200 g were used for the study. The animals were handled according to the guidelines for animal care of the United State's National Institute of Health, and the research was approved by the Institutional Ethics Committee. The rats were divided into four groups (A, B, C, and D), of five rats each. Normal rat chow and water was provided *ad libitum* throughout the experimental period.

25 g of KBrO<sub>3</sub> (Windia Speciality Chemical LTD, India) was obtained from a reputable shop in Onitsha, Nigeria. This was dissolved in 1 litre of distilled water, and the appropriate dose for each group was calculated. The control group did not receive any treatment, while the test groups were given oral doses of 0.1 mg/kg, 0.2 mg/kg, and 0.3 mg/kg of KBrO<sub>3</sub> solution, respectively for 28 days via orogastric tube.

At the end of the experiment (day 29), all the animals were anaesthetized with ketamine hydrochloride (100 mg/kg, i.p.), and was secured into a perfusion tray. The rib cage was cut-open to expose the heart. The rat was quickly perfused transcardially with 0.9 % buffered saline for about four minutes and 10 % buff-

ered formalin for three minutes. The whole brains were then removed and fixed in 10% buffered formalin. The cerebral cortex was dissected, processed for paraffin wax embedding and routinely stained for histological study using haematoxylin and eosin technique and glial fibrillary acidic protein immunohistochemical reaction for astrocytes.

## RESULTS

#### **Histological study**

The control section of the cerebral cortex showed the developing cortical layers, namely; the marginal layer (I), cortical layer (II), and subcortical layers (III). There was scanty cellular population in the marginal layer, while the cortical and subcortical layers contained pyramidal and granular-shaped cells (Fig. 1A). In animals that received 0.1 mg/kg of KBrO<sub>3</sub>, the section of the cerebral cortex showed some hypertrophied cells with some cells having karyorrhectic appearance compared to the control group (Fig. 1B). In animals that received 0.2 mg/kg of KBrO<sub>3</sub>, the section of the cerebral cortex showed hypertrophied cells, with some cells having karyorrhectic appearance compared to the control group (Fig. 1C). In animals that received 0.3 mg/kg of KBrO<sub>3</sub>, the section of the cerebral cortex showed cells with pyknotic appearance compared to the control group (Fig. 1D).

#### Astrocytes

The cerebral cortex of group A (control) animals showed immuno expression of GFAP within the cell body and processes of the astrocytes (Fig. 2A). The cerebral cortex of the 0.1 mg/kg of KBrO<sub>3</sub> test group showed no difference in the GFAP expression compared to the control (Fig. 2B). The cerebral cortical section of 0.2 mg/kg of KBrO<sub>3</sub> test group showed decreased expression of GFAP in the cell bodies and processes compared to the control group (Fig. 2C), while the section of the cerebral cortex of 0.3 mg/kg of KBrO<sub>3</sub> test group showed marked decreased expression of GFAP in the cell bodies and processes compared to the control group (Fig. 2D).

#### DISCUSSION

This study investigated the histological and immunohistochemical effects of KBrO<sub>3</sub> on the cerebral cortex of Wistar rats. The results of this study on the sections of the cerebral cortex showed hypertrophy of cells and karyorrhectic features in some, in the animals administered 0.1 mg/kg of KBrO<sub>3</sub>. There was hypertrophy of cells and karyorrhectic features in some cells in the cerebral cortex of animals administered 0.2 mg/kg of KBrO<sub>3</sub>, while the cerebral cortex of animals administered 0.3 mg/kg of KBrO<sub>3</sub> showed atrophied and pyknotic cells compared to the control group. Hypertrophy and hyperplasia of cells are usual physiological mechanisms by which cells adjust to changes in their environment, however, this does not rule out the adjustment due to adverse conditions (Huether and McCance 2008). In this study, hypertrophy could have resulted from the adverse effect of KBrO<sub>3</sub> as it is reported to cause chromosome aberration (Ishidate et al, 1984), oxidative damage and histological changes in other body organs and the brain (Le Page et al, 1995; Wahba and Ibrahim 2013; Akanji et al. 2008; Oyewo et al. 2013). Pyknosis and karyorrhexis were also observed, and these are cellular degenerative changes resulting from either necrosis or apoptosis (Kumar et al. 2005; Kroemer et al. 2009), which may have been induced by KBrO<sub>3</sub> administration. Cortical cells undergo-




Fig. 1: Representative photomicrographs of sections of the cerebral cortex of Wistar rats. A. The control group showing layers of the cerebral cortex: I= marginal layer, II= cortical layer, III= subcortical layer. Within these layers were different cell types (arrows). B. 0.1 mg/kg KBrO3 group showing some hypertrophied cells (Hy) with some having karyorrhectic appearance (k). C. 0.2 mg/kg KBrO<sub>3</sub> group showing hypertrophied cells (Hy), with some cells having karyorrhectic appearance (arrows). D. 0.3 mg/kg KBrO<sub>3</sub> group showing showed cells with pyknotic (Pyk) appearance. H & E, ×400.




Fig. 2: Representative photomicrographs of sections of the cerebral cortex of Wistar rats. A. The control group showing expression of GFAP within the cell body and processes of astrocytes (arrow heads). B. 0.1 mg/kg  $KBrO_3$  group showing no difference in the GFAP expression (arrows) compared with the control group. C. 0.2 mg/kg  $KBrO_3$  group showing decreased expression of GFAP in the cell bodies and processes (arrows) compared with the control group. D. 0.3 mg/kg  $KBrO_3$  group showing marked decreased expression of GFAP in the cell bodies and processes (arrows) compared with the control group. D. 0.3 mg/kg  $KBrO_3$  group showing marked decreased expression of GFAP in the cell bodies and processes (arrows) compared with the control group. GFAP, ×400.

ing these degenerative features are known to- result in loss or modification of functions (Bredesen et al. 2006). These degenerative changes may eventually lead to the death of the entire brain area.

The cerebral cortex from animals that received 0.1 mg/kg of KBrO<sub>3</sub> showed no difference in the GFAP expression compared to the control. This may be that the 0.1 mg/kg of KBrO<sub>3</sub> may not have been sufficient to alter astrocytic protein expression. There was less expression of GFAP in animals that received 0.2 mg/kg of KBrO<sub>3</sub> and 0.3 mg/kg of KBrO<sub>3</sub> compared with the control group. Less expression of glial fibrillary acidic protein (GFAP) in the 0.2 mg/kg of KBrO3 and 0.3 mg/kg of KBrO<sub>3</sub>, test groups is indicative of inhibitory or destructive action which these concentrations of  $KBrO_3$  may have had on the astrocytic protein expression. It has been reported that GFAP expression decreases in Down's syndrome, schizophrenia, bipolar disorder and depression, in response to acute infection or neurodegeneration (Johnston-Wilson et al. 2000), in Wernicke's encephalopathy (Cullen and Halliday 1994), in chronic infections involving HIV-1 (Levi et al. 1993), varicella zoster (Kennedy et al. 1994) and pseudorabies (Rinaman et al. 1993). As neurodegeneration was reported in the present study, this may be a reason for the decreased GFAP expression.

GFAP is an intermediate filament expressed in the central nervous system in astrocytes (Jacque et al. 1978; Venkatesh et al. 2013). The low GFAP expression may be detrimental to the structure and functions of the astrocyte, as it is involved in many important CNS processes, including cell communication and the functioning of the blood brain barrier, metabolism and in adjusting the filament network present in the cell (Kimelberg et al. 1993; Figley and Stroman 2011).

On the other hand, GFAP expression usually increases when the tissue is exposed to adverse conditions, often as a result of reactive astrocytes or astrogliosis. In astrogliosis, the astrocyte demonstrate stellate morphology, increased GFAP, immunoreactivity, increased number of mitochondria, as well as elevated enzymatic and non enzymatic antioxidant toxic activities (Eng et al. 2000; Gabyryel and Tizeciak 2001). However, this was not the case in the present study. The ability of astrocytes to protect neurons against toxic action of free radicals depends on their specific energy metabolism, high glutathione level and increased antioxidant enzyme activity (Gabyryel and Tizeciak 2001), which may have been altered negatively with KBrO<sub>3</sub> administration.

Chemically induced neurodegeneration is usually characterized by different patterns of neuronal cell death, gliosis, swollen or destroyed axons or destruction of the myelin sheath (Cavenagh 1984). However, KBrO<sub>3</sub> effect on the cerebral cortex presented different degenerative features that may affect the normal structural and functional activities of this brain area, which may eventually lead to a total breakdown of the whole body.

# CONCLUSIONS

The results of this study showed that the tested high doses of  $KBrO_3$  resulted in adverse cellular adaptations and loss of astrocytic proteins especially at the higher dosages. This may result in the functional impairment of the cerebral cortex.

## Conflict of Interest

None declared.

## REFERENCES

Akanji, M. A., Nafiu, M. O. and Yakubu, M. T. (2008) Enzyme activities and histopathology of selected tissues in rats treated with potassium bromate. African Journal of Biomedical Research.11: 87-95.

Bredesen, D. E., Rao, R. V. and Mehlen, P. (2006) Cell death in the nervous system. Nature. 443(7113): 796-802.

Cavenagh, J. B. (1984) The problems of neurons with long axons. Lancet. 2: 1284-1287.

Cullen, K. M. and Halliday, G. M. (1994) Chronic alcoholics have substantial glial pathology in the forebrain and diencephalon. Alcohol and Alcoholism (Oxford, Oxfordshire). S2: 253-257.

DeAngelo, A. B., George, M. H., Kilburn, S. R., Moore, T. M. and Wolf, D. C. (1998) Carcinogenicity of potassium bromate administered in the drinking water to male B6C3F(1) mice and F344/N rats. Toxicologic Pathology. 26: 587-594.

Ekop, A. S., Obot, I. B. and Ikpatt, E. N. (2008) Antinutritional factors and potassium bromate content in bread and flour samples in Uyo metropolis. E-Journal of Chemistry. 5(4): 736-741.

Emeje, M. O., Ofoefule, S. I., Nnaji, A. C., Ofoefule, A. U. and Brown, S. A. (2010) Assessment of bread safety in Nigeria: Quantitative determination of potassium bromate and lead. African Journal of Food Science. 4(6): 394-397.

Eng, L. F. Ghirnikar, R. S. and Lee, Y. L. (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochemical Research. 25(9-10): 1439-1451.

Figley, C. R. and Stroman, P. W. (2011) The role(s) of astrocytes and astrocyte activity in neurometabolism, neurovascular coupling, and the production of functional neuroimaging signals. European Journal of Neuroscience. 33(4): 577-588.

Gabyryel, B. and Tizeciak, H. (2001) Role of astrocytes in pathogenesis of ischemic brain injury. NeuroToxicol-ogy. 3(2): 205-221.

Hayashi, M., Kishi, M., Sofuni, T. and Ishidate, M. (1998) Micronucleus tests in mice on 39 food additives and eight miscellaneous chemicals. Food and Chemical Toxicology. 26(6): 487-500.

Huether, S. E. and McCance, K. L. (2012) Understanding Pathophysiology. 5th Ed. St Louis: Elsevier-Health Sciences Division.

IARC (1986) Potassium bromate: Evaluating carcinogenic risk to humans. International Agency for Research on Cancer Monograph. 40: 207-220.

Ishidate, M., Sofuni, T., Yoshikawa, K., Hayashi, M., Nohmi, T., Sawada, M. and Matsuoka, A. (1984) Primary mutagenicity screening of food additives currently used in Japan. Food and Chemical Toxicology. 22: 623-636.

Jacque, C. M., Vinner, C., Kujas, M., Raoul, M., Racadot, J. and Baumann, N. A. (1978) Determination of glial fibrillary acidic protein (GFAP) in human brain tumors. Journal of the Neurological Sciences. 35(1): 147-155. Johnston-Wilson, N. L., Sims, C. D., Hofmann, J. P., Anderson, L., Shore, A. D., Torrey, E. F. and Yolken, R. H. (2000) Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. Molecular Psychiatry. 5(2): 142-149.

Kawachi, T., Yahagi, T., Kada, T., Tazima, Y., Ishidate, M., Sasaki, M. and Sugiyama, T. (1980) Cooperative programme on short-term assays for carcinogenicity in Japan. In: Montesano, R., Bartsch, H. and Tomatis, L., eds. Molecular and Cellular Aspects of Carcinogen Screening Tests. Lyon: IARC Scientific Publications. 27: 323-330.

Kennedy, P. G., Major, E. O., Williams, R. K. and Straus, S. E. (1994) Down-regulation of glial fibrillary acidic protein expression during acute lytic varicellazoster virus infection of cultured human astrocytes. Virology. 205(2): 558-562.

Keser, S., Yilmaz, O. and Tuzcu, M. (2011) The effects of potassium bromate and resveratrol on cholesterol and vitamin E Levels in heart, muscle and brain of Wistar rats. Gazi University Journal of Science. 24(2): 181-186.

Kimelberg, H. K., Jalonen, T. and Walz, W. (1993) Regulation of the brain microenvironment: transmitters and ions. In Murphy, S. Astrocytes: Pharmacology and Function. San Diego: Academic Press. P. 193-222.

Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., Hengartner, M., Knight, R. A., Kumar, S., Lipton, S. A., Malorni, W., Nuñez, G., Peter, M. E., Tschopp, J., Yuan, J., Piacentini, M., Zhivotovsky, B. and Melino, G. (2009) Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death and Differentiation. 16: 3-11.

Kumar, V., Abbas, A. K. and Fausto, N. (2005) Anemia. Robbins and Cotran: Pathologic Basis of Disease. Philadelphia: Elsevier Saunders. P. 1504.

Kurokawa, Y., Maekawa, A., Takahashi, M. and Hayashi, Y. (1990) Toxicity and carcinogenicity of potassium bromate, a new renal carcinogen. Environmental Health Perspectives. 87: 309-335.

Le Page, F., Margot, A., Grollman, A. P., Sarasin, A. and Gentil, A. (1995) Mutagenicity of a unique 8- ox-

oguanine in a human Ha-ras sequence in mammalian cells. Carcinogenesis. 16: 2779-2784.

Levi, G., Patrizio, M., Bernardo, A., Petrucci, T. C. and Agresti, C. (1993) Human immunodeficiency virus coat protein gp120 inhibits the beta-adrenergic regulation of astroglial and microglial functions. Proceedings of the National Academy of Science. 90(4):1541-1545.

Nakamura, M., Murakami, T., Himata, K., Hosoya, S. and Yamada, Y. (2006) Effects of reducing agents and baking conditions on potassium bromate in bread. Cereal Foods World. 51(2): 69-73.

Oinuma, T. (1974) 8 cases of death by intoxication of potassium bromate [in Japanese]. Nichidaiishi. 33: 759-766.

Oyewo, O. O., Onyije, F. M. and Awoniran, P. O. (2013) Hepatotoxic effect of potassium bromate on the liver of Wistar rats. Journal of Morphological Science. 30(2): 107-114.

Rinaman, L., Card, J. P. and Enquist, L. W. (1993) Spatiotemporal responses of astrocytes, ramified microglia, and brain macrophages to central neuronal infection with pseudorabies virus. The Journal of Neuroscience. 13(2): 685-702.

Umemura, T., Kanki, K., Kuroiwa, Y., Ishii, Y., Okano, K., Nohmi, T., Nishikawa, A. and Hirose, M. (2006) In vivo mutagenicity and initiation following oxidative DNA lesion in the kidneys of rats given potassium bromated. Cancer Science. 97: 829-835.

Venkatesh, K., Srikanth, L., Vengamma, B., Chandrasekhar, C., Sanjeevkumar, A., Mouleshwara Prasad, B. C. and Sarma, P. V. (2013) In vitro differentiation of cultured human CD34+ cells into astrocytes. Neurology India. 61(4): 383-388.

Wahba, H. M. A. and Ibrahim, T. A. A. (2013) Protective effect of flaxseed oil and vitamin E on potassium bromate-induced oxidative stress in male rats. International Journal of Current Microbiology and Applied Sciences. 2(9): 299-309.

WHO (1992) Evaluation of certain food additives and contaminants. Expert Committee on Food Additives. Geneva: World Health Organization. P. 25-30.

Wolf, D. C., Crosby, L. M., George, M. H., Kilburn, S. R., Moore, T. M., Miller, R. T. and DeAngelo, A. B. (1998) Time- and dose-dependent development of potassium bromate-induced tumors in male Fischer 344 rats. Toxicologic Pathology. 26: 724-729.

© Copyright Nigerian Journal of Neuroscience. All rights reserved.